Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet’s Disease

Overview

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.

Full Title of Study: “A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet’s Disease (BEAN)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 23, 2027

Interventions

  • Drug: Apremilast
    • Participants will receive apremilast orally.
  • Drug: Placebo
    • Participants will receive the matching placebo orally.

Arms, Groups and Cohorts

  • Experimental: Apremilast
    • Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
  • Placebo Comparator: Placebo to Apremilast
    • Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.

Clinical Trial Outcome Measures

Primary Measures

  • Area Under the Curve for the Number of Oral Ulcers from Week 0 Through Week 12 (AUCw0-12)
    • Time Frame: Week 0 to Week 12

Secondary Measures

  • Number of Oral Ulcers from Week 0 to Week 12
    • Time Frame: Week 0 to Week 12
  • Change from Week 0 to Week 12 in the Pain of Oral Ulcers
    • Time Frame: Week 0 to Week 12
    • Pain of oral ulcers will be measured by a visual analog scale (VAS). The participants will be asked to place a vertical line on a 100 mm VAS at the point that represents the severity of oral ulcer pain. The scale will range from “no pain” (left hand boundary) to “worst possible pain” (right hand boundary).
  • Complete Response Rate for Oral Ulcers
    • Time Frame: Week 12
    • Complete response rate for oral ulcers is defined as the proportion of participants who are oral ulcer free at Week 12.
  • Proportion of Participants at Week 12 Whose Number of Oral Ulcers is Reduced by Greater Than or Equal to 50% from Week 0
    • Time Frame: Week 0 to Week 12
  • Complete Response Rate for Genital Ulcers
    • Time Frame: Week 12
    • Complete response rate for genital ulcers is defined as the proportion of participants (with genital ulcers at week 0) who are genital ulcer free at Week 12.
  • Change from Week 0 to Week 12 in Disease Activity
    • Time Frame: Week 0 to Week 12
    • Disease activity is measured by Behçet’s Disease Current Activity (BDCAF) scores. The BDCAF consists of 3 component scores: the Behçet’s Disease Current Activity Index (BDCAI) score, the Patient’s Perception of Disease Activity, and the Clinician’s Overall Perception of Disease Activity. The BDCAI score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. The Patient’s Perception of Disease Activity and the Clinician’s Overall Perception of Disease Activity were assessed by the subject and the clinician, respectively, using a scale of 1 to 7, where a higher score indicates a higher level of disease activity.
  • Proportion of Participants at Week 12 Who Have New-onset or Recurrence of Behçet’s-related Manifestations (Other than Oral and Genital Ulcers)
    • Time Frame: Week 12
  • Change from Week 0 to Week 12 on the Short Form Survey (SF-10)
    • Time Frame: Week 0 to Week 12
    • The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning.
  • Number of Participants with a Treatment-emergent Adverse Event
    • Time Frame: Up to Week 56
  • Occurrence, Severity, and Frequency of Suicide/Suicide-related Ideations and Behaviors as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
    • Time Frame: Up to Week 56
    • The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior is defined as the number of participants who answer “yes” at any time during the study (up to end of safety follow-up, Week 56) to one of the 10 categories: Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide
  • Change from Week 0 to Week 52 in Tanner Staging
    • Time Frame: Week 0 to Week 52
    • Tanner Staging of sexual development assessment will be used to assess sexual maturity. Tanner Staging assessment consists of 3 domains (pubic hair, breast development, and other changes) for girls and 4 domains (pubic hair, penis development, testes development, and other changes) for boys. Stages range from 1-5, with 1 indicating preadolescent and 5 adult.
  • Change in Body Weight Measurements
    • Time Frame: Week 0 to Week 56
  • Change in Height Measurements
    • Time Frame: Week 0 to Week 56
  • Change in Body Mass Index (BMI)
    • Time Frame: Week 0 to Week 56
    • BMI assessed as weight/(height/100)^2
  • Plasma Concentrations of Apremilast
    • Time Frame: Up to Week 52
  • Taste and Acceptability of Apremilast
    • Time Frame: Week 0 and Week 2
    • Taste and acceptability will be assessed using a questionnaire with a 7-point faces Likert Scale, with 1 ranging from “super bad” to 7 “super good” and questions to determine whether the participants are able to take the treatment medication.
  • Proportion of Participants Who Require Protocol-prohibited Medications due to Worsening of Behçet’s Disease
    • Time Frame: Week 0 to Week 12

Participating in This Clinical Trial

Key Inclusion Criteria

  • Male or Female participants 2 to < 18 years of age at randomization. – Diagnosed with behçet's disease (BD) meeting the International Study Group for Behçet Disease (ISGBD) criteria at any time prior to the screening visit. – Oral ulcers that occurred ≥ 3 times within the 12-month period prior to the screening visit. – Participant must have ≥ 2 oral ulcers at both the screening visit and on day 1. – Participant has had prior treatment with ≥ 1 non-biologic BD therapy, such as, but not limited to, topical corticosteroids or systemic treatment. Key Exclusion Criteria – Behcet's disease-related active major organ involvement – pulmonary (eg, pulmonary artery aneurysm), vascular (eg, thrombophlebitis), gastrointestinal (eg, ulcers along the gastrointestinal tract), and central nervous system (CNS) (eg, meningoencephalitis) manifestations, and ocular lesions (eg, uveitis) requiring immunosuppressive therapy; however: – Previous major organ involvement is allowed if it occurred ≥1 year prior to the screening visit and is not active at time of enrollment – Participants with mild BD-related ocular lesions not requiring systemic immunosuppressive therapy are allowed – Participants with BD-related arthritis and BD-skin manifestations are also allowed. – Previous exposure to biologic therapies for the treatment of BD oral ulcers, previous biologic exposure is allowed for other indications (including other manifestations of BD).

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Amgen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • MD, Study Director, Amgen
  • Overall Contact(s)
    • Amgen Call Center, 866-572-6436, medinfo@amgen.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.